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Abstract
Permeation of the cell membrane leading to cell death is a mechanism used by a large number of membrane-lytic peptides.
Some are linear, mostly helical, and others contain one or more disulfide bonds forming L-sheet or both L-sheet and K-helix
structures. They are all soluble in solution but when they reach the target membrane, conformational changes occur which let
them associate with and lyse the membrane. Some lytic peptides are not cell-selective and lyse different microorganisms and
normal mammalian cells, while others are specific to either type of cells. Despite extensive studies, the mode of action of
membrane-lytic peptides is not fully understood and the basis for their selectivity towards specific target cells is not known.
Many studies have shown that peptide-lipid interactions leading to membrane permeation play a major role in their activity.
Membrane permeation by amphipathic K-helical peptides has been proposed to occur via one of two general mechanisms:
(i) transmembrane pore formation via a ‘barrel-stave’ mechanism; and (ii) membrane destruction/solubilization via a ‘carpet’
mechanism. This review, which is focused on the different stages of membrane permeation induced by representatives of
amphipathic K-helical antimicrobial and cell non-selective lytic peptides distinguishes between the ‘carpet’ mechanism, which
holds for antimicrobial peptides versus the ‘barrel-stave’ mechanism, which holds for cell non-selective lytic
peptides. ß 1999 Elsevier Science B.V. All rights reserved.
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1. Introduction
Membrane-lytic peptides are cytolytic peptides
that serve in the vertebrate and invertebrate world
for both o¡ensive and defensive purposes. They
have been isolated from insects, amphibians, and
mammals. Lytic peptides can be classi¢ed into three
major groups: those which are active selectively
against eucaryotic cells, procaryotic cells or both eu-
caryotic and procaryotic cells. Antimicrobial pep-
tides are the largest group within these families.
They were found initially in invertebrates [1], but
later on also in vertebrates, including humans [2,3].
They are used as a cell-free defense mechanism in
addition to, or complementary to, the highly speci¢c
cell-mediated immune response [4]. This secondary,
chemical immune system provides organisms with a
repertoire of small peptides that are promptly syn-
thesized upon induction, and act against invasion by
occasional and obligate pathogens [1,5^7]. So far,
more than 400 di¡erent antimicrobial peptides have
been isolated and characterized. Most of the antimi-
crobial peptides are composed of L-amino acids, with
de¢ned K-helix or L-sheet secondary structures. Some
are linear, mostly helical, without cysteines, while
others contain one or more disul¢de bonds, forming
L-sheet or both L-sheet and K-helix structures [1,8].
In most cases, the peptides’ mode of action appears
to be by direct lysis of the pathogenic cell membrane.
A second native group of peptides antibiotics,
although smaller, is composed of both L- and D-ami-
no acids. This group includes gramicidins, actinomy-
cins, bacitracin, polymyxins, lantibiotics and bomb-
inins H 3^5 [9^11]. The co-existence of L- and D-
amino acids gives rise to unique structures and prop-
erties that are completely di¡erent from the all-L-
peptides. One important example is the group of lin-
ear gramicidins [12], peptide antibiotics composed of
alternating L- and D-amino acids, that form L-type
helices with a hydrogen bonding pattern of the back-
bone similar to that in L-sheets. In these L-helices the
amino acid residues are pointing outward and the
carbonyl moieties are alternately pointing upward
and downward in the interior of the helix, providing
the helices with a hydrophilic pore.
Membrane-lytic peptides have been studied exten-
sively in order to understand general aspects related
to peptide-lipid interactions, as well as the relation of
these interactions to the biological function of these
peptides. The largest and most studied group out of
those described above includes short linear polypep-
tides (v40 amino acids) which are devoid of disul¢de
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bridges (see reviews in [5,6,13]). These polypeptides
vary considerably in chain length, hydrophobicity
and overall distribution of charge, but share a com-
mon K-helical structure when associated with phos-
pholipid membranes [13]. Some of these peptides are
not cell selective (e.g. the bee venom melittin [14,15]),
the Moses sole ¢sh lytic peptide pardaxin [16,17], and
the human cathelicidin-like LL-37 [18], being able to
lyse both bacterial and mammalian cells. Others are
selective either to mammalian cells but not to bacte-
ria (e.g. N-hemolysin from Staphylococcus aureus) [19]
or vice versa, i.e. cytotoxic to various pathogenic
microorganisms but not to normal mammalian cells
(e.g. cecropins, isolated from the cecropia moth [20]
and from the hemolymph and cuticular extracts of
other Lepidopteran and Dipterian insects (for a re-
view, see [21,22]), magainins [23] and dermaseptins
[24^26], both isolated from the skin of frogs. Each
antimicrobial peptide has a broad but not identical
spectrum of antimicrobial activity, providing the host
maximum coverage against a rather broad spectrum
of microbial organisms.
Despite extensive studies, the mode of action of
this group of antibacterial and cytolytic polypeptides
is not fully understood and the basis for their selec-
tivity towards speci¢c target cells is not known.
2. Peptide-membrane interaction
2.1. Phospholipid head group charge and peptide
charge distribution dictate the target for
membrane-lytic peptides
It is clear that peptide-lipid interactions, rather
than receptor-mediated recognition processes, play
a major role in the function of most membrane-lytic
peptides. This has been demonstrated with the cell
non-selective lytic peptide melittin and the antimicro-
bial peptides cecropin and magainin, in which their
analogues composed entirely of D-amino acids (enan-
tiomers) possess lytic activity indistinguishable from
that of the parent molecules [27^29]. These enan-
tiomers preserved the amphipathic K-helical structure
of the wild-type peptides, a structure proposed to be
a prerequisite for their function. However, the ¢nd-
ing that diasteriomers of lytic peptides (containing
both L- and D-amino acids) are able to lyse bacteria
similarly to the all-L-amino acid parent peptide, de-
spite the fact that their amphipathic structure was
altered, suggests that even the K-helical structure is
not necessary for activity [30^32]. Another common
feature found in most native membrane-lytic peptides
is that the distribution and the amount of the net
charge correlate with their biological function; pep-
tides with a low net negative charge (e.g. N-hemoly-
sin), or with a low net positive charge spread along
their helix backbone (e.g. pardaxin, melittin) are
mostly lytic to mammalian cells or to both mamma-
lian and bacterial cells. On the other hand, native
non-hemolytic antibacterial peptides contain high
net positive charge contributed by a large number
of basic amino acids which are distributed along
the hydrophilic face of the amphipathic K-helix.
This feature has been proposed to account for their
preferential activity against bacteria and not normal
mammalian cells. Bacterial membrane is rich in
acidic phospholipids [33]. Therefore, the net positive
charge of the antibacterial peptides facilitates their
perturbing activity towards bacterial membrane. In
contrast, the outer membrane of human erythrocytes
(representatives of normal mammalian cells) is com-
posed predominantly of zwitterionic phosphatidyl-
choline (PC) and sphingomyelin phospholipids [34].
Indeed, studies on the interaction of antimicrobial
peptides with model phospholipid membranes re-
vealed low a⁄nity to zwitterionic phospholipids
compared to acidic phospholipids. This has been
demonstrated with cecropins [35,36], magainins [37^
41], dermaseptins [42,43] and others [30^32,44]. In
addition, the outer surface of Gram-negative bacteria
contains negatively charged lipopolysaccharides
(LPS). The role of the outer membrane and LPS in
the interaction between magainin 2 and the Gram-
negative cell envelope was studied by FTIR spectros-
copy [45]. Magainin 2 alters the thermotropic proper-
ties of the outer membrane-peptidoglycan complexes
from wild-type Salmonella typhimurium and a series
of LPS mutants which display di¡erential susceptibil-
ity to the bactericidal activity of cationic antibiotics.
LPS mutants show a progressive loss of resistance to
killing by magainin 2 as the length of the LPS poly-
saccharide moiety decreases. While disruption of out-
er membrane structure most likely is not the primary
factor leading to cell death, the susceptibility of
Gram-negative cells to magainin 2 has been proposed
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to be associated with factors that facilitate the trans-
port of the peptide across the outer membrane, such
as the magnitude and location of LPS charge, the
concentration of LPS in the outer membrane, outer
membrane molecular architecture, and the presence
or absence of the O-antigen side chain. Nevertheless,
there is not always a direct correlation between bind-
ing to LPS and antimicrobial activity. For example,
it has been suggested that the reduced antimicrobial
activity of gramicidin S analog families is the result
of their increased a⁄nity to outer membrane compo-
nents of Gram-negative microorganisms, and there-
fore compete for binding to the inner membrane [46].
It should be noted that although electrostatic inter-
actions between cationic peptides and negatively
charged bacterial cell envelope components may be
important, human erythrocytes, for example, contain
a large number of highly negatively charged sialic
acid-containing carbohydrate moieties in the form
of glycoproteins and glycosphingolipids, which
form the glycocalx layer. However, binding and pen-
etration are less e⁄cient in the eucaryotic clycocalx.
The low a⁄nity of antimicrobial peptides for zwit-
terionic membranes might explain their inability to
lyse erythrocytes. However, there are exceptions.
Functional studies with dermaseptin S4 [47] and the
human-like cecropin, LL-37 [48], demonstrated that
they bind and permeate e⁄ciently both zwitterionic
and negatively charged phospholipid vesicles, com-
pared to other native antibacterial peptides, which
permeate e⁄ciently only negatively charged mem-
branes. The high a⁄nity of these peptides towards
zwitterionic PC phospholipid membranes is surpris-
ing in light of their high net positive charge. This
may suggest the involvement of hydrophobic inter-
actions between the peptides and the zwitterionic
membranes. LL-37 and dermaseptin S4 reach PC
membranes as oligomers. Since the N-terminus of
both peptides is hydrophobic, a bundle of N-terminal
regions could initiate binding to the membrane.
2.2. Proposed mechanisms for the mode of action of
amphipathic K-helical membrane-lytic peptides
Two alternative mechanisms were proposed to de-
scribe the detailed steps involved in membrane per-
meation by amphipathic K-helical lytic peptides.
These models di¡er conceptually from each other.
In the ¢rst one, the ‘barrel-stave’ model [49], amphi-
pathic K-helices insert into the hydrophobic core of
the membrane and form transmembrane pores. In
the second one, the ‘carpet’ model [42], the peptides,
which do not need necessarily to adopt amphipathic
K-helical structure, are in contact with the lipid head
group during the whole process of membrane perme-
ation and do not insert into the hydrophobic core of
the membrane. A major question is whether a par-
ticular mechanism can be assigned to a particular
biological function (i.e., antibacterial activity versus
cytotoxicity to mammalian cells).
The purpose of this review is to summarize several
studies on the mode of action of lytic peptides with
relation to the above question. The list of lytic pep-
tides studied, which is by no means exhaustive, in-
cludes several linear naturally occurring all-L-amino
acids peptides, as well as their diasteriomers, in
which several L-amino acids were substituted with
their D-amino acids. Most of these studies were per-
formed with model phospholipid membranes and
several ambiguities which might arise using these
model systems have been described in the relevant
articles. Nevertheless, since phospholipid head
groups have a major contribution to the activity of
lytic peptides, they should be the best model system
rather than negatively charged aliphatic compounds
such as phosphatidic acid.
C
Fig. 1. A cartoon illustrating the ‘barrel-stave’ (to the right) and the ‘carpet’ (to the left) models suggested for membrane permeation
(modi¢ed from [48]). In the ‘carpet’ model the peptides are bound to the surface of the membrane with their hydrophobic surfaces
facing the membrane and their hydrophilic surfaces facing the solvent (step A). When a threshold concentration of peptide monomers
is reached, the membrane goes into pieces (steps B and C). At this stage a transient pore is formed. In the ‘barrel-stave’ model pep-
tides ¢rst assemble in the surface of the membrane, then insert into the lipid core of the membrane following recruitment of additional
monomers.
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2.3. ‘Barrel-stave’ model for transmembrane
channel/pore formation
The ‘barrel-stave’ mechanism [49] describes the
formation of transmembrane channels/pores by bun-
dles of amphipathic K-helices, such that their hydro-
phobic surfaces interact with the lipid core of the
membrane and their hydrophilic surfaces point in-
ward, producing an aqueous pore (Fig. 1, right pan-
el). The following criteria must be ful¢lled in order
that a molecule would form a transmembrane pore:
(i) monomers bind to the membrane in an K-helical
structure; (ii) monomers recognize each other in the
membrane-bound state already at low surface density
of bound peptide; (iii) helices insert into the hydro-
phobic core of the membrane; and (iv) progressive
recruitment of additional monomers occurs to in-
crease the pore size. A very crucial step in this mech-
anism is the assembly of monomers on the surface of
the membrane before the peptide is inserted, since it
is energetically unfavorable for a single amphipathic
K-helix to traverse the membrane as a monomer. In
the latter case, the low dielectric constant and inabil-
ity to establish hydrogen bonds will not allow the
fatty acyl region of a lipid bilayer to be in a direct
contact with a polar surface of a single amphipathic
K-helix. Based on these criteria, it is unlikely that the
helices will be highly homogeneously charged be-
cause their hydrophilic surfaces are facing each other
while forming a transmembrane pore. Furthermore,
it is reasonable to assume that since these peptides
can insert into the hydrophobic core of the mem-
brane, their interaction with the target membrane is
driven predominantly by hydrophobic interactions,
and as a consequence they should bind to phospho-
lipid membranes irrespective of their charge.
2.4. ‘Carpet’ model for membrane disruption
The ‘carpet’ model was proposed for the ¢rst time
to describe the mode of action of dermaseptin S [42],
and later on was used to describe the mode of action
of other antimicrobial peptides, such as dermaseptin
natural analogues [43,47], cecropins [50,51], the hu-
man antimicrobial peptide LL-37 [48], caerin 1.1 [52],
Trichogin GA IV [53], and diasteriomers of lytic pep-
tides [30^32]. The model describes a situation in
which lytic peptides are in contact with the phospho-
lipid head group throughout the entire process of
membrane permeation. According to this model,
lytic peptides initially bind onto the surface of the
target membrane and cover it in a carpet-like man-
ner. Membrane permeation occurs only if there is a
high local concentration of membrane-bound pep-
tide. High local concentration on the surface of the
membrane can occur either after all the surface of the
membrane is covered with peptide monomers, or al-
ternatively, after there is an association between
membrane-bound peptides, forming a localized ‘car-
pet’. In the ‘carpet’ model, contrary to the ‘barrel-
stave’ model, peptides are not inserted into the hy-
drophobic core of the membrane (left panel in Fig.
1), neither do they assemble with their hydrophilic
surfaces facing each other. Furthermore, a peptide
that permeates the membrane via this mechanism
does not necessarily require the adoption of a speci¢c
structure upon its binding to the membrane. Initial
interaction with the negatively charged target mem-
brane is electrostatically driven, and therefore pep-
tides are positively charged. The four steps proposed
to be involved in this model are: (i) preferential bind-
ing of peptide monomers to the phospholipid head
groups; (ii) alignment of the peptide monomers on
the surface of the membrane so that their hydrophilic
surface is facing the phospholipid head groups or
water molecules; (iii) rotation of the molecule lead-
ing to reorientation of the hydrophobic residues to-
ward the hydrophobic core of the membrane; and
(iv) disintegrating the membrane by disrupting the
bilayer curvature. An early step before the collapse
of the membrane packing may include the formation
of transient holes in the membrane. Holes like these
may enable the passage of low molecular weight mol-
ecules prior to complete membranal lysis. The for-
mation of such holes was proposed to describe the
mode of action of dermaseptin [54] and magainin
[55^57], and named a toroidal (or wormhole) model
(step B in left panel of Fig. 1). As seen in Fig. 1,
these holes may allow the passage of peptide mole-
cules from the outer membrane into the inner mem-
brane of, for example, Gram-negative bacteria in a
process which may be referred to as ‘self-promoting
uptake’ [58^61].
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2.5. Steps involved in peptide-membrane interaction
which de¢ne a particular mode of action
Based on the criteria described above, an attempt
to determine the mechanism by which a particular
membrane-lytic peptide interacts with and induces
leakage of molecules from phospholipid membranes
needs to address several questions with regard to the
steps involved in the process.
(a) Is the binding of the peptide to the membrane
electrostatically driven or does it result from hydro-
phobic interactions?
(b) Does the peptide reach the membrane as
monomers or oligomers?
(c) Is there an association between membrane
bound peptide monomers before or after a threshold
concentration occurs?
(d) Is there a cooperativity in the peptide binding
process?
(e) Does the peptide insert into the hydrophobic
core of the phospholipid membrane or lie on the
surface?
(f) What is the structure of the peptide in the mem-
brane-bound state?
3. Di¡erent methods used to measure membrane-
binding properties of lytic peptides may yield
di¡erent conclusions
The ability of cytolytic peptides to bind to phos-
pholipid membranes has been investigated using a
variety of methods. Most of these methods utilized
small or large unilamellar vesicles composed of lipids
with di¡erent compositions. These methods can be
classi¢ed into three major groups: (a) methods that
monitor the initial steps involved in membrane bind-
ing (i.e., a step in which one or very few molecules
bind to one vesicle), and as a result, the morphology
and integrity of the vesicles is not altered (e.g. £uo-
rescence studies with highly sensitive £uorescence
probes, as well as studies with radiolabeled peptides);
(b) methods that are not sensitive enough to follow
the initial steps of binding but vesicle morphology is
preserved or slightly altered (e.g. £uorescence studies
with tryptophan-containing peptides, equilibrium di-
alysis and circular dichroism (CD) spectroscopy);
(c) methods that correlate peptide binding to mem-
brane leakage, i.e. membrane integrity is altered. The
latter method might be suitable only if membrane
binding correlates directly with membrane leakage,
since peptides can bind strongly to vesicles but not
cause leakage of their contents [62].
Using di¡erent methods to investigate binding of a
particular peptide to membranes may sometimes lead
to con£icting conclusions. For example, the positive
cooperativity of membrane permeabilization by mag-
ainin observed in di¡erent systems suggested that the
oligomerization of lipid-bound magainin is impor-
tant for its activity. The formation of active associ-
ated structures was indicated by the positive cooper-
ativity of membrane permeabilization and cytotoxic
activity [63]. Positive cooperativity was also observed
for magainin binding to lipid bilayers, derived from
calcein leakage studies of negatively charged lipid
vesicles, and the dependence of the £uorescence
quantum yield of bound tryptophan-containing mag-
ainin on surface concentration [64,65]. These results
suggested the existence of preformed associates
which were expected to facilitate pore formation
[64,65]. The pore model suggested by Matsuzaki et
al. [55,65] assumed a side-by-side dimerization of
magainin helices. However, a direct study of Schu-
mann et al. [66], examining the state of association of
magainin analogues using £uorescence energy trans-
fer, revealed that the experimentally determined
transfer e⁄ciency was lower than that predicted for
monomeric magainin analogues randomly distrib-
uted exclusively at the outer lea£et of lipid vesicles.
Furthermore, for tryptophan-containing magainin
and for a diasteriomer of magainin in which two D-
amino acids substituted two L-amino acids, an iden-
tical energy transfer e⁄ciency was observed,
although the non-helical double D-amino acid-substi-
tuted analogue should have a signi¢cantly reduced
association tendency resulting in decreased £uores-
cence energy transfer (FET). Disturbance of the am-
phipathic helix of magainin by double D-amino acid
substitution should also signi¢cantly reduce the for-
mation of magainin associates and consequently de-
crease FET caused by association. The conclusion of
this study was that magainin is not associated in its
membrane bound state. These two con£icting results
can be accommodated in the carpet model (Fig. 1) as
follows: magainin binds initially to the surface of the
membrane as monomers and only after a threshold
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concentration has been reached, transient pores are
formed which allow the leakage of £uorescent
marker.
4. Initial steps in the binding, insertion and
organization in membranes of lytic peptides
The interfaces, de¢ned by the distribution of the
water associated with the phospholipid polar head
groups, are each about 15 Aî thick and consist of a
complex and thermally disordered mixture of water,
head groups, glycerol, carbonyl, and methylenes
from the edges of the hydrocarbon core [67]. These
regions are rich in possibilities for non-covalent in-
teractions with peptides. Several studies, which are
described in the following paragraphs, indicate that
antimicrobial peptides are located at the interface,
parallel to the surface of the membrane, without
deeply inserting into the acyl chain region, whereas
cell non-selective lytic peptides tend to insert into the
hydrophobic core of the membrane.
4.1. The binding process
Tryptophan £uorescence has been used in many
studies to determine binding and environmental
changes in lytic peptides. Tryptophan £uorescence
is sensitive to the environment and increases upon
interaction with membranes. However, in many cases
the quantum yield of tryptophan is not su⁄cient to
follow the initial steps in the binding process, espe-
cially if the binding is weak. It has been reported that
tryptophan £uorescence is strongly a¡ected by the
surrounding amino acids. Eight side chains of natu-
rally occurring amino acids can quench tryptophan
£uorescence: the amide groups of glutamine and as-
paragine, the carboxyl groups of glutamic and as-
partic acids, the lysine-amino group, tyrosine phenol,
cysteine sulfhydryl, and histidine imidazole [68].
Therefore, results may be sometimes confusing. For
example, incorporation of tryptophan-containing
peptides into membranes may result in £uorescence
decrease rather than increase. This may happen if the
lytic peptide forms oligomers in solution and the
tryptophan is buried within a hydrophobic core of
the oligomers. In addition, Yau et al. [69] have
shown that tryptophan prefers membrane surfaces
and this preference is more likely dominated by tryp-
tophan’s £at rigid shape, that limits access to the
hydrocarbon core, and its Z electronic structure
and associated quadrupolar moment (aromaticity),
that favor residing in the electrostatically complex
interface environment.
A highly sensitive spectro£uorometric approach
has been developed to investigate the molecular
mechanism by which cell-selective and cell non-selec-
tive membrane-lytic peptides permeate phospholipid
membranes. Peptides were labeled with £uorescent
probes having high extinction coe⁄cients either at
their carboxy or amino termini [17,35,42,43,70^74].
Various spectroscopic assays were then utilized to
study the interaction of the labeled peptides with
phospholipid membranes. This approach enabled
the separate identi¢cation of the three steps involved
in membrane permeation by lytic peptides: the bind-
ing process, surface/membranous localization of the
monomers when bound to the membrane, and their
assembly/non-assembly within the membrane.
The environmentally sensitive NBD (7-nitrobenz-
2-oxa-1,3-diazole-4-yl) probe [75] was used as a
marker for membrane binding [73,76] since its £uo-
rescence can increase up to approx. 10-fold upon
interaction with membranes. The higher wavelength
Fig. 2. Binding isotherms of NBD-labeled peptides to phospho-
lipid vesicles. The binding isotherms were derived from binding
curves of NBD-labeled peptides titrated with phospholipid
vesicles, by plotting Xb* (molar ratio of bound peptide per 60%
of lipid) versus Cf (equilibrium concentration of the free pep-
tide in solution). Data were taken from [35,43,73,85].
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used for excitation (approx. 467 nm) and the high
quantum yield reduce signi¢cantly the contribution
of light scattering. Therefore, when attached to a
particular polypeptide this probe can be used to de-
termine whether this polypeptide binds to mem-
branes and its localization therein. NBD-labeled pep-
tides exhibit £uorescence emission maxima around
540 nm in solution, re£ecting a hydrophilic environ-
ment for the NBD moiety [35,42,73,77]. However,
upon addition of phospholipid vesicles, NBD-labeled
membrane-lytic peptides exhibited increases in their
£uorescence intensities and blue shifts of their emis-
sion maxima. This change re£ects the relocation of
the NBD group into a more hydrophobic environ-
ment. The depth of penetration can be evaluated
from the value of the blue shift, which varies from
approx. 520 nm (for membrane-inserted peptides) to
approx. 530 nm (for peptides that are surface local-
ized). The advantage of the use of the NBD moiety is
that it allows the use of experimental conditions
in which the lipid/peptide molar ratio ranges
from 6 100:1 up to s 15 000:1. The lytic peptide
pardaxin [73,74], and several antimicrobial peptides
from the dermaseptin [42,43,47] and cecropin
[35,50,78] families, including the human like cecro-
pin, LL-37 [48], were labeled selectively at their N-
terminal amino acid with the £uorophore NBD with-
out altering signi¢cantly their biological function. In
the presence of vesicles, NBD-labeled antimicrobial
peptides exhibited increases in their £uorescence and
blue shifts in the emission maxima towards 528^533
nm, which re£ect a situation in which the NBD
group is located at or near the surface of the mem-
brane (emission maximum of approx. 530 nm)
[42,77]. In contrast to these results, the channel-form-
ing pardaxin had its emission maxima at approx. 520
nm, revealing interaction with the hydrophobic core
of the membrane [73].
The NBD moiety also facilitates the calculation of
partition coe⁄cients of membrane-binding peptides
at very low peptide concentrations (6 0.1 WM) and
very high lipid:peptide molar ratios (approx.
15 000:1). Compared to NBD, tryptophan £uores-
cence and CD spectroscopy studies are mostly car-
ried out at a peptide concentration which is about
10^100-fold higher, respectively. Fig. 2 shows exam-
ples of binding isotherms obtained for pardaxin, the
K-5 helix of N-endotoxin (both channel/pore forming
peptides), as well as for two antimicrobial peptides,
cecropin and dermaseptin B. Such binding isotherms
are obtained as described in detail elsewhere
[35,42,73,79^81], using the following formula:
Xb* = Kp*Cf , where Xb* is de¢ned as the molar ratio
of bound peptide in the outer lea£et of the vesicles
(60% of total lipids), Kp* corresponds to the appar-
ent partition coe⁄cient, while Cf represents the equi-
librium concentration of free peptide in the solution.
Partition coe⁄cients can be directly calculated from
these curves. The binding isotherm of pardaxin [73]
and the K-5 helix of N-endotoxin [82] exhibit sharp
increases in their slopes as the peptide/lipid molar
ratio increases (high Cf value). This argues in favor
of a process whereby peptides ¢rst incorporate into
the membrane and then aggregate [79]. However, the
binding isotherms of dermaseptin [42] and cecropin B
[35] were found to be practically straight lines, indi-
cating a simple binding process. However, straight
Fig. 3. Theoretically and experimentally derived percentage of
energy transfer versus bound-acceptor/lipid molar ratios. The
amount of lipid-bound acceptor (Rho-peptides), Cb, at various
acceptor concentrations was calculated from the binding iso-
therms. First, the fractions of bound acceptor, Fb, were calcu-
lated for the various peptide/lipid molar ratios from their bind-
ing isotherms. The energy transfer expected for a random
distribution of the monomers assumes R0 = 51.1 Aî as deter-
mined for membrane-bound NBD-Rho pair [74]. Data were
taken from [42,74,35,43,50,48].
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lines cannot exclude a situation whereby oligomers of
small sizes are formed.
4.2. Oligomeric state, orientation and depth of
penetration of membrane-lytic peptides
Cooperativity in the binding process may indicate
whether a particular peptide can form large aggre-
gates already at the initial step of binding. However,
peptides can also assemble without cooperativity.
The ability of lytic peptides to assemble in the mem-
brane can be detected using FET between a donor
and an acceptor pair. FET experiments were per-
formed with NBD- or £uorescein (Flu)-labeled (en-
ergy donors) and rhodamine (Rho)-labeled (energy
acceptors) peptides [35,42,74]. This pair of donor/
acceptor permitted the measurement of peptide
assembly in vesicles at lipid:peptide molar ratios of
s 5000:1, conditions in which as few as 2^10 peptide
molecules are bound to a single vesicle. When the
percentage of energy transfer was plotted versus the
various molar ratios of ‘bound-acceptor (Cb)’/lipid,
the resulting curves always revealed high FET with
cell non-selective pore-forming peptides such as par-
daxin and the K-5 helix of N-endotoxin. However,
FET observed with non-hemolytic antimicrobial pep-
tides resembled that of randomly distributed mono-
mers, but sometimes increased after a threshold con-
centration occurred. Fig. 3 shows examples of FET
versus acceptor:lipid molar ratios in negatively
charged membranes, for the cell non-selective par-
daxin, the slightly hemolytic human LL-37, and the
non-hemolytic antimicrobial peptides cecropin B, ce-
cropin P, dermaseptin S and dermaseptin B. Interest-
ingly, dermaseptin B showed high FET, and the lip-
id:peptide molar ratio at which the peptide induced
membrane permeation occurred before the entire sur-
face of the vesicles was covered, which might suggest
that it is not acting via the ‘carpet’ mechanism. How-
ever, dermaseptin B binds in a non-cooperative man-
ner onto the surface of the membrane, has a weaker
a⁄nity to zwitterionic membranes compared to neg-
atively charged membranes, and has lytic activity on
bacteria similar to that of other antimicrobial pep-
tides. In addition, a mean ¢eld method was used for
simulation of the interactions of dermaseptin B with
lipid bilayers, which included an approximate repre-
sentation of the electrostatic e¡ects of the head
group region of the bilayer [83]. This study showed
that the surface-associated orientation appears to be
the most stable arrangement of this peptide. A pos-
sible interpretation of these results is that dermasep-
tin B associates when bound the surface of the mem-
brane and forms a local ‘carpet’, but not a
transmembrane pore via a ‘barrel-stave’ mechanism.
The human LL-37 also oligomerizes in zwitterionic
membranes. However, NBD £uorescence studies and
polarized attenuated total re£ectance Fourier trans-
form infrared (ATR-FTIR) spectroscopy revealed
that the peptide is predominantly K-helical and ori-
ented nearly parallel to the surface of zwitterionic
lipid membranes, observations which do not support
the channel forming hypothesis but rather the ‘car-
pet’ mechanism [48]. Similarly to dermaseptin B and
LL-37, when tryptophan-containing magainin inter-
acted with phosphatidylglycerol (PG) and phospha-
tidylserine (PS) membranes, a much lower peptide:
lipid molar ratio was required to induce leakage of
calcein from PG vesicles compared to PS vesicles
[84]. These results where interpreted in favor of a
non-‘carpet’ mechanism with PG membranes versus
a ‘carpet’ mechanism for PS membranes.
ATR-FTIR was used to determine the secondary
structure and orientation within phospholipid mem-
branes of the mammalian cecropin P1 (CecP) [78].
The shape and frequency of the amide I and II ab-
sorption peaks of the peptide within acidic phospha-
tidylethanolamine (PE)/PG multibilayers in a 7:3
(w/w) ratio (a phospholipid composition similar to
that of many bacterial membranes), indicated that
this peptide is predominantly K-helical. Using polar-
ized ATR-FTIR spectroscopy, it was found that the
peptide is preferentially oriented nearly parallel to
the surface of the lipid membranes. In addition, mo-
lecular dynamics simulations con¢rmed that, in re-
sponse to a cis positive transmembrane voltage dif-
ference [78], CecP adopts an orientation parallel to
the membrane surface and does not insert into the
bilayer. ATR-FTIR and £uorescence spectroscopy
were also used in the study of the human LL-37,
indicating that similarly to other antimicrobial pep-
tides, the peptide binds preferentially onto the sur-
face of both negatively charged and zwitterionic
membranes [48]. In contrast, ATR-FTIR spectros-
copy revealed that the K-5 helix of the pore-forming
peptide N-endotoxin is inserted into the hydrophobic
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core of the membrane rather than lying on the sur-
face of the membrane [85].
Solid-state NMR measurement of 15N-labeled
magainin oriented in multilamellar membranes [86^
89], Raman [38], £uorescence [65] and di¡erential
scanning calorimetry measurements [64], all indicated
that at high and moderate lipid:peptide ratios, mag-
ainin is oriented parallel to the membrane surface,
associated with the lipid head group, and does not
signi¢cantly disturb the aliphatic chain region. For
example, three analogues of magainin 2, each having
a Trp residue substituted for Phe at the 5th, 12th, or
16th position, were synthesized and investigated [65].
The depths of the Trp residues, which were deter-
mined using the n-doxylphosphatidylcholine quench-
ing technique, were about 10 Aî from the bilayer
center irrespective of the peptide aggregational state,
suggesting that the orientation of the magainin 2 K-
helix is parallel to the membrane surface.
4.3. The e¡ect of membrane-lytic peptides on the acyl
chain organization
Linear amphipathic K-helical antimicrobial pep-
tides have little e¡ect on the structure of the acyl
chain of lipid bilayers when inserted in phospholipid
membranes, whereas cell non-selective lytic peptides
have a stronger e¡ect. In a Raman study [38], the
spectrum of the lipid acyl chain C-C stretching re-
gion was used to indicate the extent of acyl chain
disorder induced by bound peptides. Magainin did
not disrupt signi¢cantly the acyl chains of negatively
charged and zwitterionic membranes, even at a high
peptide-to-lipid ratio (w/w) of 1. The e¡ect of mag-
ainin 2 on the gel to liquid crystalline phase transi-
tion of multilamellar vesicles was measured using
di¡erential scanning calorimetry [64]. At 3.5 mol%
the e¡ect of magainin on DPPG’s (dipalmitoylphos-
phatidylglycerol) main transition seemed insigni¢-
cant, leading to the conclusion that magainin does
not penetrate deeply into the acyl chain region. In
another study, 2H-NMR was used to examine F16W
magainin 2 incorporated into palmitoyloleoylphos-
phatidylglycerol (POPG)/deuterated palmitoyloleoyl-
phosphatidylcholine (POPC) (1:3) MLV [90]. The
results showed that the presence of the peptide only
slightly decreased the order parameter of the double
bond of the PC chain.
Polarized ATR-FTIR spectroscopy was used to
determine the e¡ect of cecropin P1 on the multibi-
layer acyl chain order [78]. The incorporation of ce-
cropin P1 did not signi¢cantly change the order pa-
rameters of the acyl chain of PE/PG (7:3 w/w)
multibilayers (that mimic the phospholipid composi-
tion of Escherichia coli [91]), suggesting that the pep-
tide does not penetrate the hydrocarbon core of the
membranes. Similar results were found with LL-37
[48]. Contrary to these results, signi¢cant e¡ects on
the acyl chain were observed with membrane-inserted
hemolytic peptides such as melittin [92,93], N-hemo-
lysin [92], the K4-K5 hairpin helices from Bacillus
thuringiensis N-endotoxin [85], transmembrane seg-
ments of phospholamban [94,95] and colicin A [96].
4.4. Initial formation of secondary structure and
insertion into the interface between the lipid head
group and the acyl chain
The conformational changes that take place during
the insertion process of membrane-lytic peptides into
membranes are not clearly known. One model sug-
gests that the secondary structure formation of an
amphipathic K-helical structure is attained through
sequential stages of interfacial binding in an unfolded
state, secondary structure formation, and insertion of
secondary structure units into the lipid bilayers, lead-
ing to disruption of the membrane [97]. This model is
supported by a study that examined the conforma-
tional changes of the bee venom melittin upon inser-
tion into phospholipids. The results showed that me-
littin adsorbed on the lipid layer surface contains less
K-helix than its counterpart inserted into the lipid
layer. As the penetration depth of melittin increased,
more ordered structures (K-helix) appeared [98].
Before binding to membranes most antimicrobial
peptides are present in an aqueous solution as mono-
mers in an unfolded state. There are a few excep-
tions, such as dermaseptin S4 [47] and LL-37
[18,48], which are in equilibrium with oligomers in
which the peptides exist in an K-helical conforma-
tion. The initial step of their insertion into the mem-
brane is adsorption of the unfolded form on the sur-
face of the negatively charged phospholipid
membrane, as described above. Forces a¡ecting the
free energy cost of inserting unfolded peptide into
phospholipid membranes include the hydrophobic
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interactions between the non-polar amino acids and
the phospholipid hydrocarbon layer. These forces are
countered by the cost of partitioning the polar amino
acids and the peptide bond (CONH) [99]. When
bound to negatively charged membranes, the positive
charges of antimicrobial peptides are partially neu-
tralized by the negative charges of the phospholipid
head groups, thus reducing the energy cost of ad-
sorbing the peptide into the membrane. Subse-
quently, this may allow the intrinsic hydrophobic
forces to manifest themselves by forming a stable
K-helical structure, driving the peptide further into
the interface [83]. However, with the zwitterionic
phospholipids the rate limiting step appears to be
the initial binding of the antimicrobial peptide to
the surface, which is very low. As indicated previ-
ously, LL-37 and dermaseptin S4 bind strongly also
to zwitterionic membranes. However, the N-termini
of both peptides are hydrophobic and they form
oligomers in solution. Therefore, a bundle of hydro-
phobic N-terminus regions can initiate binding to the
membrane.
5. The membrane permeation process
5.1. Peptide-induced changes in the membrane
curvature
The initial step involved in membrane permeation
and micellization requires a change in the curvature
of the membrane. Membrane-lytic peptides can be
classi¢ed into two groups in terms of their e¡ect on
membrane curvature [100]. (i) Inducers of a negative
curvature strain (class L peptides) [13]. A reciprocal
wedge model was suggested by Tyler et al. [101] in
order to explain the ability of class L peptides to lyse
cells. In this model, a class L peptide folds into an
amphipathic K-helical structure upon association
with phospholipids, such that the polar face of the
peptide is associated with the polar head groups of
the phospholipids. The lipid-associated peptide,
when viewed in cross-section, is an inverted wedge
shape in which the hydrophobic face of the helix
forms the apex. This structure is expected to force
the alkyl chains of phospholipid apart, inducing a
negative curvature on the membrane. (ii) Positive
curvature inducers (class A peptides [13,102], cyclic
tachyplesin I and magainin). Class A peptides and
tachyplesin I have been shown to cause micellization
of bilayers [103,104]. In a recent study the e¡ect of
magainin 2 on membrane curvature was examined
[84]. Magainin 2 was found to signi¢cantly raise
the TH value of DPOPE (dipalmitoleoyl-L-K-phos-
phatidylethanolamine), suggesting that in the absence
of electrostatic e¡ects the peptide imposes positive
curvature strain on the membrane. Phosphatidylser-
ine, phosphatidic acid, and cardiolipin, as opposed to
phosphatidylglycerol, are known to form the hexag-
onal II phase under conditions of reduced interlipid
electrostatic repulsion [105^107]. Permeation of
phosphatidylserine, phosphatidic acid, and cardio-
lipin by magainin 2 occurred at much higher P/L
values than phosphatidylglycerol, indicating that lip-
ids that impose higher negative curvature strain on
membranes are more resistant to magainin cytolytic
activity. Furthermore, addition of a sublytic concen-
tration of cone-shaped LPC (palmitoyl-L-K-phospha-
tidylcholine), which imposes a positive curvature
strain, facilitated magainin’s leakage activity. A
high positive curvature in a dimension perpendicular
to the bilayer plane is required to stabilize a pore
structure toward the formation of a micelle. Two-
dimensional 1H-NMR experiments in membrane
mimetic environments showed that magainin 2
[108], cecropin A [109] and cecropin P1 [110] are
composed of two helical regions with a £exible hinge
in between. The ability of amphipathic antimicrobial
peptides to induce positive membrane curvature may
depend on this wedge-like shape. The role of £exible
hinge in antibacterial activity has been previously
demonstrated with a series of cecropin-like model
peptides [111].
5.2. Antimicrobial peptides permeate membranes after
a local threshold concentration has been reached
In order to form micelles, a peptide needs to reach
high concentration at a certain area of the mem-
brane. In accordance with this assumption, liposome
leakage and cytotoxicity experiments suggested the
existence of concentration-dependent changes in the
membrane permeating activity of amphipathic anti-
microbial peptides. In addition, these studies re-
vealed that initial steps involved in micelle formation
include transient holes in the membrane, and changes
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in the orientation of the peptides. Below a critical
concentration magainin causes only slight leakage,
but at higher concentrations magainin causes wide-
spread lysis [37,38,64,63,112^115]. A few examples
may demonstrate this e¡ect. (i) The kinetics of mag-
ainin 2-induced release of 6-carboxy£uorescein (CF)
from phosphatidylserine liposomes, indicating that
the fast release of dye is a transient e¡ect resulting
from transient destabilization of the bilayer upon
initial interaction with the peptide [115]. No measur-
able CF release could be observed until a high level
of bound magainin was achieved. (ii) The ability of
magainin 2 to decrease the membrane potential in
cytochrome oxidase liposomes was investigated by
Juretic et al. [63]. At low concentrations the peptide
was almost inactive, but activity was observed when
a critical concentration has been reached. (iii) Neu-
tron in-plane scattering detected pores formed by
magainin 2 in membranes only when a substantial
fraction of the peptide is oriented perpendicular to
the membrane [57]. (iv) The interaction of magainin
2 and its analogue Ala19-magainin 2 with lipid was
investigated using two lipid photolabels. The results
indicated a concentration-dependent insertion of the
peptide into the lipid bilayer. Higher photolabeling
at both shallow and deep photolabels was achieved
at high peptide-to-lipid molar ratio [116].
Membrane permeation combined with membrane
binding studies on dermaseptins [42,43,47] and cecro-
pins [35,50] revealed that maximal activity was ob-
tained when the peptides covered the surface of the
liposomes. In addition, dermaseptins [42,43], cecro-
pin B, cecropin P ([35,50]; unpublished results) and
cecropin A [117] dissipated ion gradients at low con-
centrations of peptide, while substantially higher
concentrations were required to release encapsulated
calcein. Further support was obtained by Steiner et
al. [118], who found that the stoichiometry of cecro-
pin killing of bacteria suggested that amounts of ce-
cropin su⁄cient to form a monolayer strongly modi-
¢ed the bacterial membrane. In another study, a
survival assay was used in order to compare the con-
centrations of cecropin A required to kill bacteria to
the concentration required to release cytoplasmic L-
galactosidase [117]. The results clearly demonstrated
that cecropin A is bactericidal at relatively high con-
centrations, where it increases membrane permeabil-
ity to large molecules.
5.3. Membrane permeation by antimicrobial peptides
revealed by electron microscopy
Examination of E. coli treated with cecropins at
concentrations below the minimal inhibitory concen-
trations (MIC) by transmission electron microscopy
revealed the formation of patches, whereas total lysis
of the bacteria was observed at the MIC concentra-
tion [119]. These patches were similar to those ob-
tained with non-cytolytic derivatives of pardaxin
[120] and diasteriomers of lytic peptides [30,31].
When magainin was used at a concentration where
bacterial viability had decreased about 30%, similar
blebs were observed on the cell surface of the bac-
teria [121]. At higher concentrations magainin 2 pro-
duced string-like structures, which are considered to
be cellular debris arising from cell lysis. Similar re-
sults were obtained when isolated Heliothis cecropin
and cecropin B were incubated with E. coli K12 D31
[122]. Large parts of the cell envelope were missing
from the bacteria and the outer membrane appeared
to be dissociated from the cell. E. coli cells contained
large lesions with an outer diameter of 9.3 nm and
internal pore diameter of 4.2 nm. Scanning and
transmission electron microscopy were used to study
the morphological changes induced by cecropin B on
the bacterial cell of Klebsiella pneumoniae [123]. The
results showed that cecropin B causes bleb-like pro-
trusions on the bacterial cell surface.
5.4. A detergent-like e¡ect in membrane permeation
by antimicrobial peptides
Comparison between the abilities of magainin 2
and the micelle-forming detergents Triton-100 and
octyl glucoside to induced leakage of CF from PS
indicated that their speci¢c activities are similar.
The onset of dye leakage took place at a magainin
concentration of approx. 3 mole%. Similar results
were obtained with Triton-100 and octyl glucoside
[115]. The addition of magainin at a high concentra-
tion to phospholipid bilayers resulted in the appear-
ance of large water-¢lled bilayer disruptions [57]. 31P
solid state NMR spectroscopy detected the optical
clearing of dense suspensions and the formation of
isotropic phases [124].
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6. Summary and concluding remarks
Functional and structural studies with several
membrane-lytic K-helical peptides presented in this
chapter are in agreement with either the ‘barrel-stave’
model (right panel of Fig. 1) or some or all of the
steps involved in the ‘carpet’ model (left panel of Fig.
1). Cell non-selective amphipathic K-helical lytic pep-
tides permeate membranes predominantly by form-
ing pores via a ‘barrel-stave’ mechanism. These pep-
tides bind to both zwitterionic and negatively
charged membranes, oligomerize at a very low pep-
tide:lipid molar ratio, bind cooperatively to mem-
branes, insert into the hydrophobic core of the mem-
brane, form single channels at very low peptide
concentration and cause leakage of vesicles content
at very low peptide:lipid ratios. However, amphi-
pathic K-helical antimicrobial peptides permeate
membranes predominantly via the ‘carpet’ mecha-
nism. In addition, despite the fact that linear antimi-
crobial peptides were developed by distant and di-
verse species during millions of years of evolution,
they share common motifs, i.e. they are linear, pos-
itively charged and have a high propensity to adopt
an amphipathic K-helical conformation in hydropho-
bic environments. The studies presented in this chap-
ter have demonstrated the essential role of these
properties in the di¡erent stages involved in mem-
brane permeation according to the ‘carpet’ model.
This review focused mainly on cecropins, derma-
septins, magainins and LL-37 as representatives of
the amphipathic K-helical antimicrobial peptides.
The fact that these peptides vary with regard to their
length, amino acid composition, and net positive
charge, but act via a common mechanism, may imply
that other linear antimicrobial peptides exhibiting the
same properties, also share the same ‘carpet’ mecha-
nism.
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